Larimar Therapeutics, Inc.

NASDAQ:LRMR

Biotechnology

Healthcare
$3.23 +0.99%

+$0.04 today

Market cap
$337.45M
Beta
0.82
P/E (TTM)
-1.8
EPS (TTM)
-$1.95
52W Low $2.22High $6.42

Volume 1.41M

Average 1.73M

LRMR Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Larimar Therapeutics, Inc.NASDAQ: LRMR

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses dips below year-ago levels

Q1 FY2026 operating expenses of $31.12M fell 0.2% year over year, behind the +63.7% change in trailing-twelve-month operating expenses. Sequentially, it fell 51.4% from the prior quarter. Over 3 fiscal years it compounded at +67.8% a year.

Context

  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -0.2% toward the trailing-twelve-month pace of +63.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$31.12M-51.4% QoQ
Last fiscal yearDec 2025
$172.5M+89.8% YoY
LTMMar 2026
$172.43M+63.7% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.2%——
1 year+89.8%——
3-year CAGR+67.8%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
172.5M USD
Year-over-year change
+89.8%
4-year CAGR
+36.0%

Operating Expenses vs competitors

How LRMR compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +63.7% is the highest of 11, against a peer median of -12.8%.
  • Over three fiscal years its annual growth of +67.8% compares with a peer median of +14.2%.
LRMR Competitors
Operating Expenses for LRMR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANNXAnnexon, Inc.LTM Mar 2026$203.15M USD+11.1%+13.5%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$172.43M USD+63.7%+67.8%—
DBVTDBV Technologies S.A.LTM Mar 2026$164.05M USD+44.9%+13.2%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$162.92M USD+24.9%+67.1%—
AMRNAmarin Corporation plcLTM Mar 2026$150.13M USD-11.1%-27.1%69.9%
ENGNenGene Holdings Inc.LTM Apr 2026$132.21M USD+50.3%+85.1%—
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$97.24M USD-16.4%+21.3%—
KRROKorro Bio, Inc.LTM Mar 2026$85.57M USD-14.7%+14.9%2227.3%
ALTAltimmune, Inc.LTM Mar 2026$81.97M USD-16.5%+2.5%227697.2%
ACIUAC Immune S.A.LTM Mar 2026CHF 68.45M CHF-14.4%-1.1%1849.0%
ANROAlto Neuroscience, Inc.LTM Mar 2026-$55.19M USD-179.1%+31.6%—
Peer median (excluding LRMR) —-12.8%+14.2%2038.1%

Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development38.4M24.25M27.67M73.28M154.22M
Selling, General & Admin12.07M12.28M14.09M17.61M18.27M
Operating Expenses50.47M36.53M41.76M90.89M172.5M
Depreciation & Amortization326K318K311K318K350K
EBITDA(50.31M)(35.04M)(36.64M)(80.29M)(165.32M)
EBITDA Margin—————
Operating Income(50.47M)(36.53M)(41.76M)(90.89M)(172.5M)
Operating Margin—————
Interest Income00000
Interest Expense00000
Other Income / Expenses(171K)1.17M4.81M10.29M6.82M
Income Before Tax(50.64M)(35.36M)(36.95M)(80.6M)(165.67M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(50.64M)(35.36M)(36.95M)(80.6M)(165.67M)
Net Margin—————
EPS (Basic)(2.93)(1.33)(0.84)(1.32)(2.27)
EPS (Diluted)(2.93)(1.33)(0.84)(1.32)(2.27)
Weighted Avg Shares17.16M25.76M43.9M61.26M72.95M
Weighted Avg Shares (Diluted)17.16M25.76M43.9M61.26M72.95M

Larimar Therapeutics, Inc.

NASDAQ:LRMR

Intrinsic Alpha fair value

Locked

Current Price

$3.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.